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ABSTRACT
Rotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-speciﬁc death
among young children. Effective vaccines have recently been approved and successful vaccination
program implemented. The aim of this study was to evaluate the cost effectiveness of mass rotavirus
vaccination program in Iran. We developed a Markov model that reﬂects key features of rotavirus natural
history. Parameters of the model were assessed by ﬁeld study or developed through literature search and
published data. We applied the model to the 2009 Iranian birth cohort and evaluated the cost-
effectiveness of including the rotavirus vaccine (Rotarix®) into Iranian expanded immunization program
(EPI). With an estimated hospitalization rate of 0.05 and outpatient rate of 0.23 cases per person-year,
vaccinating cohort of 1231735 infants in Iran with 2 doses of (Rotarix®), would prevent 32092
hospitalizations, 158750 outpatient visits, and 1591 deaths during 5 y of follow-up. Under base-case
assumption of $10 cost per course of vaccine, the vaccination would incur an extra cost of $1,019,192
from health care perspective and would avert 54680 DALYs. From societal perspective, there would be
$15,192,568 saving for the society with the same averted DALYs. The incremental cost effectiveness ratio
showed a cost of $19 US dollars per averted DALY from health care perspective and a saving of $278 US
dollars for each averted DALY from societal perspective. Introducing rotavirus vaccine into EPI program






Rotavirus is a leading cause of morbidity among children less
than 5 y in both developed and developing countries. 2008, the
burden of diarrhea due to rotavirus was estimated 453000
deaths and 27 million medical visits and majority of these took
place in low and middle income countries.1,2 In low income
countries the median age at the primary rotavirus infection
ranges from 6 to 12 months whereas in high income countries,
the ﬁrst episode may be delayed for 2 to 3 y.2,3,4 induces partial
immunity and subsequent (secondary and tertiary) infections
are presented clinically mild or asymptomatic.5 Introduction of
rotavirus vaccination in 2006 has had major effect on reducing
the burden of rotavirus diarrhea in countries with mass vacci-
nation program.6 At present, there are 2 vaccines licensed
(Rotarix® by GlaxoSmithKline and RotTeq® by Merk) and their
ﬁeld effectiveness documented in the range of 50% in some
African countries to more than 90% in European countries.2,7
Both vaccines are recommended by WHO and provide similar
beneﬁts at similar cost for low and middle income countries.
Rotavirus vaccine has been introduced in national immuniza-
tion program of many countries such as Mexico, Brazil, USA,
Australia, and Belgium, South Africa.8-11 Studies of cost effec-
tiveness of rotavirus vaccine in many countries have proven to
be cost-effective from both societal and health care perspec-
tive12-17 however the mass vaccination program has been shad-
owed by the high price of vaccine18 and the variability of
vaccine’s ﬁeld effectiveness due to frequently evolving capabil-
ity of rotavirus genome.7,19 In this paper we present the result
of the cost effectiveness study of vaccination in Iran from both
health care and societal perspective.
Result
Health outcome and utilization
In the absence of vaccination at base case scenario, 5% of chil-
dren less than 5 y will be hospitalized for rotavirus diarrhea
with mean § sd(standard deviation) duration of 3.0 § 1.9 d
and 23% of children less than ﬁve years need outpatient care
for rotavirus diarrhea. In average, each case of rotavirus diar-
rhea contributes a mean § sd of 4.3 § 4.1 d of productivity
loss. With vaccination coverage of 97% and vaccine efﬁcacy at
CONTACT Alireza Mosavi Jarrahi rmosavi@yahoo.com
Supplemental data for this article can be accessed on the publisher’s website.
© 2016 Taylor & Francis
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2016, VOL. 12, NO. 3, 794–800
http://dx.doi.org/10.1080/21645515.2015.1087626
base case scenario, the hospitalization rate will decrease 13 times
(from 50 to 3 case per 1000 children per year) and the outpa-
tient care will decrease 4 times (from 228 to 64 cases per 1000
children per year). Considering the cohort of 1,231,735 infants
born in 2009 to Iranian population, the vaccination at base case
scenario would prevent 32,092 cases of hospitalizations,
158,750 cases of outpatient visits, and 1,591 deaths due to rota-
virus infection (Table 2). Translating the health outcomes into
summary measures of healthy life, vaccination would avert
54,680 DALYs (discounted at 3% per annum) among the
cohort born in 2009 (Table 2).
Cost prospect
The rotavirus infection will incur major direct hospitalization
and out-patient costs to the health care system and major indi-
rect cost related to productivity loss, transportation, and
accommodation to the society. In the absence of vaccination,
the rotavirus infection for the cohort of infant born in 2009,
would incur cost of 11,878,982 US dollars for health care per-
spective and 31,633,769 US dollars for societal perspective for
5 y follow-ups of the cohort. Vaccination program with the
base case scenario would cost 1,019,192 dollars (discounted at
3% annum) for ministry of health.
The effectiveness
In the absence of vaccination, the average DALY lost to diar-
rhea among the cohort of infant born in 2009 would be 49
DALYs per 1000 children per year and vaccination will lower
this rate to 4.3 DALYs per 1000 children per year.
The cost-effectiveness
The incremental cost effectiveness ratio (ICER) at the base case
showed a cost of 19 US dollars for each DALY averted from the
perspective of health care and a saving of 278 US dollars for each
DALY averted from the societal perspective. Considering the
WHO recommendation criteria for being cost-effective, the ICER
from both perspectives was far lower than the estimated Gross
Domestic Product (GDP) for the year 2009 (the World Bank esti-
mated GDP for Iran in 2009 was $4,931 us dollars) indicating that
the vaccination is highly cost effective in our population.
Uncertainty analysis
For both perspective (health care and societal), the ICER was
more sensitive to the incidence of diarrhea, vaccine price, and
the cost of hospitalization (Fig. 2. diagram A and B). example,
when incidence was varied between 0.16 to 0.70 cases of diar-
rhea per person-year, the incremental cost-effectiveness ratio
ranged from a cost of $75 to a saving of $286 per averted
DALY from heath care perspective (Fig. 2. diagram A). the
societal perspective, the corresponding ICER was $114 saving
for lower level of incidence and a saving of $1022 for upper
level for each DALY averted (Fig. 2. diagram B).
Vaccine price was another variable that its variability had a
major effect on the ICER from both perspectives. the price of
vaccine was set at $1 per dose, the incremental cost-
effectiveness ratio was dominant indicating saving of $156 and
$453 for health care and societal perspectives, respectively
(Fig. 3). From societal perspective, the ICER remains in a sav-
ing state for all values of the vaccine price (Fig. 3). From the
health care perspective, the saving would continue up to when
the price of vaccine passes $9 after which there is cost for
increasing the price of vaccine (Fig. 3).
In the sensitivity analysis from the societal prospective, the
loss of productivity had a large effect in cost effectiveness; the
ICER ranged from a cost of $27 to a saving of $603 dollars per
averted DALY (Table 1 and Figure 2 diagram B). The cost of
hospitalization had large effect in health care perspective; the
ICER ranged from a cost of $123 to a saving of $131 per DALY
averted for low and high values, respectively. At the societal
perspective, the low and high values of the cost of hospitaliza-
tion did not change the saving state of the program (Fig. 2
Table 1. Model input parameter values and ranges.
Variable Estimate Base Low Hi Source
Hospitalization rate (primary) Age group (in month)
2–5 0.005 0.004 0.016 Estimated refer
to appendix 1
6–11 0.018 0.013 0.055
12–23 0.020 0.014 0.062
24–35 0.004 0.003 0.013
36–59 0.004 0.003 0.011
Out Patient Rate (primary)
2–5 0.023 0.012 0.053
6–11 0.080 0.043 0.185
12–23 0.091 0.048 0.211
24–35 0.018 0.010 0.042
36–59 0.016 0.009 0.037
Mortality rate from Rotavirus
2–5 0.0003 0.0003 0.0004
6–11 0.0001 0.0010 0.0012
12–23 0.0006 0.0006 0.0007
24–35 0.0001 0.0001 0.0001
36–59 0.0001 0.0001 0.0001
Costs in Dollars per case
Hospitalization 214 73 416 Estimated
Out-Patient Visit 16 13 19 Estimated
Loss of productivity
(hospitalized)
161 3 834 Estimated
Lose of productivity
(outpatient)
54 3 278 Estimated
Transportation (Hospitalized) 11 3 40 Estimated
Transportation (outpatient) 4 2 13 Estimated
Other societal cost 27 3 120 Estimated
Vaccine cost per case 10 1 20 [16]




0.62 0.5 0.83 [6]
Ratio of third
infection VS ﬁrst
0.4 0.28 0.59 [6]
Effectiveness parameters
Discount rate 0.03 0 0.05 [50]
Disability weight 0.119 0.086 0.152 [51]
Vaccine Efﬁcacy in percent
Hospitalization 93 75 95 [16]
ﬁrst year 93 75 95 [16]
at or after 1 y of age 93 75 95 [16]
Outpatient
ﬁrst year 78 75 95 [16]
at or ﬁrst year of age 75 75 95 [16]
Death
ﬁrst year 75 75 95 [16]
at or ﬁrst year of age 93 75 95 [16]
Vaccine other parameters
Coverage 0.966 0.85 0.99 [34]
Wastage 0.05 0.02 0.15 [34]
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diagram B). The ICER was robust to vaccine efﬁcacy; discount
rate, vaccine wastage, and program cost for both perspectives
(Fig. 2 diagrams A and B).
Discussions
This study showed that the rotavirus vaccination program in
Iran appears to be highly cost effective from both health care
and societal perspective using the WHO criterion of having a
cost per averted DALY below GDP. The robustness of results of
our study depends on the assumptions of our model and the
validity of our estimated parameters. The natural history of rota-
virus infection is very complicated and this complication is
highlighted with the fact that infection does not produce a long
lasting protection and the chance of subsequent infection exists
though this chance is lower and the severity infection is milder.
The uncertainty in themagnitude and duration of partial protec-
tion can have great effect on validity of our results. Our model
addressed the chance of subsequent infection and included up to
2 subsequent infections. In the light of the fact that the number
of cases after second infection was very low, including just 2 sub-
sequent infections (instead of 3 or 4 as some studies did 20) has
not compromised validity of our result.
There was no community based study to estimate the inci-
dence of conﬁrmed cases of rotavirus in Iran. The Sentinel Hos-
pital-based Surveillance of Rotavirus Diarrhea in Iranian
(SHSRD) was not a through sample of all occurring cases and
its reported ﬁgures was not qualify to estimate the incidence of
even hospitalization in our population. Our estimated ﬁgures
for incidence were in line with other studies. In a Meta analysis
of reported incidence of rotavirus infection, the pooled estimate
was 0.24 (0.17, 0.5) per person year of observation for children
of less than 2 y Our base-case estimate of 0.24 for the ﬁrst 2 y
(based on the Table 1) is almost the same as the point of esti-
mate for reported pooled estimate. There are no studies to
report the incidence of rotavirus in countries of Middle East
except one community based study from Egypt that reported
Figure 1. The decision tree model. In this ﬁgure patient follow is shown. The ﬁrst
node represents the decision between the not vaccinated and vaccinated strategy
(displayed as square). After the decision node a Markov node follows, where possi-
ble Markov-states are deﬁned.
Figure 2. Results of one-way sensitivity analyses. This graph presents results of
univariate sensitivity analyses from the health care (A) and societal perspective (B).
The x-axis represents the ranges of the incremental cost-effectiveness ratios of vac-
cination in Iranian children when the baseline estimates of key parameters were
varied over plausible ranges. The vertical line represents the base case incremental
cost-effectiveness ratio of rotavirus vaccination. The negative values indicate sav-
ing per averted DALY.
Figure 3. The incremental cost- effectiveness ratio (ICER) for different price of vac-
cine from both health care and societal perspective.
Table 2. Result of the cost effectiveness analysis for a cohort of 1231735 children
born in 2009 in Iran.
Not Vaccinated Vaccinated Differences
Utilization
Hospitalization 42310 3217 32092
Out Patient visit 211802 53053 158750
Death 1725 156 1591
Cost (in US dollar)
Health Care 11,878,982 12,898,174 ¡1,019,192
Societal 31,633,769 16,441,202 15,192,568
Effectiveness (in DALY) 59957 5277 54680
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incidence of 0.19 per person per year among the under 5 y
which is close to our estimate.21 In addition, the many epidemi-
ologic parameters used in our study (especially the proportions
used in the incidence estimates) are in agreement with the
pooled estimates of the same parameters reported in a recent
systematic review by Mark A, et al.22 who pooled studies of
rotavirus diarrheal in countries of Middle East.
In cost effectiveness analysis of rotavirus diarrhea hospitali-
zation is a major contributing factor to overall cost effectiveness
of vaccination. Our rate of 43 hospitalizations per 1000 is very
close to the estimated regional rate of 45.9 § 25% hospitaliza-
tions per 1000 children for countries middle income in Asia13
and close to the estimate from the community based study in
Egypt 21 (30 hospitalizations per 1000 children per year).
Another major and determining factor in estimating cost
effectiveness is how accurate is the cost estimates for different
component of the model. Our estimate of the cost for hospitali-
zation was based on ﬁeld study that was design for the purpose
of this study. One limitation for this part of our estimates was
the fact that the studied population may not be a good repre-
sentative of the whole country (at least from a socio economic
stand point) but as costs of many services delivered by the gov-
ernment are similar all over the country this lack of representa-
tiveness would not have major effect in our overall result from
both perspectives.
Our base-case estimate of $214 for hospitalization and $16 for
outpatient is in the range of WHO CHOICE23 estimates for the
year of 2009 for Iran, however they are higher than estimates for
countries of similar income by Laura Jean Podewils et al.13 and
estimates by JavanbakhtM, et al.17 that estimated 174.52 for inpa-
tient and 4.69 for outpatients cost for government perspective.
The difference in our estimates from Javanbakht M, et al. esti-
mates originates from differences in methodology of estimation;
in Javanbakht M, et al., the outpatient cost (where high discrep-
ancy is seen) estimate was based on expert opinions while ours
was based on national utilization surveys and government tariff.
Both studies (the Javanbakht M, et al. and our study) used the
same methodology to estimate inpatient costs (both study used
patient’s medical records from hospitals to estimate), however
our study used patient’s records from many hospitals while they
used just one hospital. In addition, the 2 studies had different deﬁ-
nitions and cost components (for example we included loss of
productivity in our societal perspectives while they did not) that
explain the discrepancies seen in cost estimates and cost per
averted DALYs between 2 studies.
Our study has its own limitations among the most impor-
tant ones are; 1) the estimate of burden of rotavirus that was
not based on a well deﬁned community based study, 2) lack of
locally generated data on the vaccine efﬁcacy as the efﬁcacy has
been heterogeneous across different countries,7 3) the fact that
we did not include indirect effect of vaccination in our Marko
model, 4) the fact that our analysis did not include a probability
sensitivity analysis, and 5) and the fact that we did included
data on adverse effect of vaccination in our analysis.
Conclusion
Introducing rotavirus vaccine would be highly cost-effective
public health intervention in Iran.
Methods
The economic model
An age structured cohort model was used to estimate the cost
effectiveness of vaccination. The cohort of children born in 2009
to Iranian population was followed for 5 y (model’s time hori-
zon) based on 2 scenarios: 1) vaccinated with 2 doses of vaccine
(at 2 and 4 months of age), and 2) not vaccinated. The model
was structured as a Markova model with a cycle length of
2 weeks. In each cycle, a child is at risk of getting infection with
rotavirus with 3 outcomes (hospitalized or needing outpatient
care or dies of rotavirus), or survives without infection, or dies of
other causes. The cohort entered into each scenario at 2 months
of age (we assumed that no infection could happened before
2 months of age due to maternal antibodies.24 The model struc-
ture is detailed in the Figure 1. We assumed that a child can get
infection up to 3 times and after the third infection she/he will
be no longer at risk of infection that requires medical care. We
assumed that the ﬁrst exposure does produce partial immunity
that the chance of second or third infection after ﬁrst infection
will be lower compared to ﬁrst infection and the clinical presen-
tation will be moderate and just requires outpatient care (subse-
quent infection does not require hospitalization). The model
was implemented using Microsoft Excel spreadsheet.
Burden of disease
The incidence
Since there was no data on the community based incidence of
rotavirus related diarrhea in Iran, we used a comprehensive
search of literature in English and Farsi (local language) in order
to identify any relevant published estimates. The search was per-
formed on 2 databases 1) the Pubmed and 2) the IranMedex (a
database indexing published studies in Farsi language). The litera-
ture search identiﬁed; 1) 2 major community surveys that
reported the prevalence of all cause diarrhea, 2) one community
based study that reported proportion of cause speciﬁc rotavirus
diarrhea among outpatients with all cause diarrhea, 3) 9 hospital
based studies25-34 that reported the proportion of cause speciﬁc
rotavirus diarrhea among the hospitalized all cause diarrheal
patients. The two community surveys included; a World Bank
funded research that measured prevalence of diarrhea in a sample
of 5 cities throughout the country,35 and the other one reported
the result of theMultiple-Indicator Demographic andHealth Sur-
vey (MIDHS) performed in 2010.36 The World Bank study esti-
mated the rate of hospitalization and outpatient visit among the
surveyed diarrheal patients. estimate the incidence of cause spe-
ciﬁc rotavirus diarrhea, we applied the hospitalization and outpa-
tient rate from the World Bank study to the proportion of
diarrhea reported by theMIDSH study to estimate the proportion
of hospitalization and outpatient among all cause diarrheas. we
applied the proportion of rotavirus among the outpatient all cause
diarrheal from the community based study to estimate the rate of
rotavirus cause speciﬁc outpatient diarrhea in theMIDSH survey.
To estimate the rate of rotavirus hospitalization in the MIDSH
survey, we performed a ﬁxed effect meta-analysis of the propor-
tion of rotavirus diarrhea reported in the 9 hospital-based studies.
Then the pooled estimate was applied to the proportion of hospi-
talized all cause diarrhea in the MIDSH survey to estimate the
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rate of rotavirus hospitalization. The results estimated a crude
hospitalization rate of 0.05 and a crude outpatient rate of 0.23
cases per children less than 5 y per year. To estimate the age spe-
ciﬁc incidence, the age distribution of rotavirus diarrhea reported
by the “Sentinel Hospital-based Surveillance of Rotavirus Diar-
rhea in Iranian (SHSRD)”
study 25 was used and applied in the estimation process (Table 1).
The SHSRD study did not include all cases in the country and it
just included cases referred to pediatric ward of major hospitals in
selected cities (disqualifying the study to directly estimate the inci-
dence of rotavirus hospitalization). Appendix 1 provides the
details of the analysis done to estimate the incidence. As the
model included chance of second and third infection, the risk of
subsequent infection after ﬁrst infection was reduced by 62% and
40% for second and third infection, respectively. The ratios were
based on the study by Velazquez et al.5 who reported the subse-
quent risk of infection after ﬁrst and second infections.
The mortality
The all cause mortality for under 5 y in Iran accounted for 25
cases per 1000 child per year in 2009.36 The Sentinel Hospital-
based Surveillance of Rotavirus Diarrhea in Iranian (SHSRD)in
Iran25 did not report any death among 1298 conﬁrmed cases of
rotavirus during the one year follow-up. In our analysis, the
number of death due to rotavirus gastroenteritis in Iran esti-
mated by the WHO for the year 2008 was obtained from the
WHO’Immunization, Vaccines and Biologicals web site.37 The
estimated number of deaths was applied to the estimated popu-
lation of under 5 y to estimate the crude mortality rate of rota-
virus gastroenteritis for children less than 5 y The crude
mortality was converted to transition probabilities using the
same age distribution as hospitalized and the mathematical
function converting rate to probability (Appendix 1 includes
the details of the analysis).
The cost
The cost was estimated for both health care and societal per-
spectives. We used the “WHO guidelines38 for estimating the
economic burden of diarrheal diseases due to rotavirus” to esti-
mate costs whenever a reliable estimate was not available in the
literature. For this purpose, we used the population living in
the central and eastern part of the province of Tehran (geo-
graphically located 1300 km north of Persian Gulf) to measure
the cost. This population consists of close to 4 million people
living in both urban and rural areas. The cost component of
health care perspective included direct cost of hospitalization
and outpatient visit and the cost of societal perspective
included; cost of hospitalization, outpatient visit, transporta-
tion, loss of productivity, and patient visit at hospital. All costs
were measured in Rials (local currency) and converted to US
dollar based on the mid-year of 2009 currency exchange rate
declared by the Central Bank of the I.R. of Iran. All costs were
discounted at rate of 3% per year.
Cost of hospitalization
To estimate the cost of hospitalization, the medical records of
all cases of acute diarrhea referred to 4 general hospitals in the
catchment area of the study population during the year of 2009
were obtained. Detailed information about the duration of hos-
pitalization, diagnostic, treatment, and other related utilization
and their costs were abstracted from the patient’s medical
record. A patient medical record included a detailed cost of all
diagnostic and treatment procedures (hospital stay, diagnostic
procedures, treatment cost, and nursing cost). Among the 157
cases of hospitalized diarrhea referred to the 4 hospitals, 64
cases were coded as viral gastroenteritis (with ICD 10 coding of
A08.4, and A08.3). The data from the viral coded cases was
used to estimate the hospitalization cost.
Out patient cost
To estimate the average cost of outpatient visit; the pattern of
care seeking for diarrheal disease reported by the National Inte-
grated Monitoring and Evaluation Survey of Family Health
(IMESFH)39 in 2006 provided the proportion of different facili-
ties (rural health post, urban outpatient clinic, stand alone pedi-
atrician or general physician) providing outpatient care for
diarrheal patients, the prescribing indicators from the report of
the National Essential Drug Monitoring Program (NEDMP)40
provided the prescribing pattern of medication for diarrheal
diseases, and the government visiting tariff 41 for general physi-
cian, pediatrician, or other axillaries provided the cost of paying
for care giver. The combination of these parameters estimated
an average cost of 16 US dollars per each outpatient visit.
Societal cost
To estimate the societal cost, a sample of 69 patients from the
157 cases were randomly selected and the cost of transporta-
tion, days of absence from work for both mother and father,
and the cost for relative visiting patient while in hospital was
obtained by telephone interviews. The sample of 69 cases out of
157 was enough to account for expected variations on health
care utilization and socioeconomic status among the patients
for accurate cost estimation. To calculate the cost due to loss of
productivity, the average number of days of loss productivity
was multiplied by the average household income reported by
the Statistical Center of Iran42 for the year 2009.
The vaccine
Two oral rotavirus vaccines are available tomass vaccination pro-
grams; Rotarix, a monovalent P1A G1 vaccine7 (GlaxoSmithK-
line), and RotaTeq, a pentavalent bovine-human reassortant
vaccine (Merck).2,7 Rotarix is administered in a 2-dose schedule
along the ﬁrst and second dose of Diphtheria-Tetanus-Pertussis
(DTP) vaccine. RotaTeq requires a 3-dose schedule with an inter-
val of 4–10 weeks between doses.7 In this study we included just
Rotaix because of its 2-dose schedule compared to RotaTeq
which requires 3 doses (saving administrative resources). We
assumed that the vaccine will be introduced into the national pro-
gram and administered along with the DPT vaccine schedule.
The cost of vaccine
Iran is not an eligible country to beneﬁt from the WHO-UNI-
CEF Global Immunization Vision and Strategy (GIVS) Alliance
rotavirus vaccine pricing program.43 The GlaxoSmithKline that
manufactures the Rotrix, has recently reduced the price of its
vaccine to 2.5 US dollars per dose18 if large volume of purchase
is ordered. It is estimated that the price of vaccine will decline
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to a value as low as 1 US dollars per doses due to price matura-
tion by 2025.44 For our base case scenario, we assumed a cost of
$5 dollars per dose of vaccine with $0.25 US dollars per dose as
program cost (Table 1). These values have been recommended
by other investigators for countries with similar economic
level.13
The vaccine efﬁcacy, coverage, wastage
The vaccine efﬁcacy has been heterogonous in different countries
and regions of the world. The highest reported efﬁcacy has been
reported in Europe with a value of 95% and the lowest in Malawi
with a value of 45%.7 Vaccine efﬁcacy has been related to the
genotype frequency,45 severity of diarrhea, and the partial immu-
nity due to either infection or vaccination.7,29 In addition, WHO-
UNICEF suggests efﬁcacy would follow the pattern of under-5
mortality in a country and recommends that countries with simi-
lar mortality rate should use similar efﬁcacy ﬁgures for economic
evaluation of rotavirus vaccination.43 Considering the genotype
frequency and WHO recommendation, the efﬁcacy in the base
case scenario was considered 93% for hospitalization and death
and 78% for out-patient visit with reduction in efﬁcacy after the
ﬁrst year of vaccination (Table 1). The efﬁcacy ﬁgures used in our
model are ﬁgures that have been used to project the cost effective-
ness of rotavirus vaccination in Asian countries.13
The same rate of coverage and wastage for the DPT in the
EPI national program were used in our analysis. The EPI
reported a coverage rate of 97% and a wastage rate of 5% for
DPT in the year 200936 (Table 1).
Effectiveness
Disability-adjusted life-years (DALY) were used to measure the
effectiveness of the vaccination using the recommended formula
by JA Fox-Rushby and K Hanson.46 We calculated Years of lost
life (YLL) for each case of death due to rotavirus and Years of
life lived with disability (YLD) for each case of outpatient and
hospitalization. In calculating DALY, the age weighting parame-
ter of 0.04, disability weight of 0.119,47 diarrhea duration of
5 days, and the life expectancy based on the WHO life expec-
tancy estimates for Iran for the year 2009 were used.48 We used
DALY with age-weighting scheme to have our result comparable
with other studies. DALYs were discounted at 3% per year.
Uncertainty analysis
Sensitivity analysis was conducted on all the variables in the
model that were considered to be uncertain. Tornado diagram
was used to assess the magnitude of uncertainties and their
effects on the cost-effectiveness ratio. With the price maturation
andmarket variability of the price of vaccine, we run a cost effec-
tiveness threshold analysis on varying prices of vaccine.
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